Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I Dose Finding Study of BI 765063, a Monoclonal Antibody (mAb) Antagonist of SIRPα, as Single Agent and in Combination With BI 754091, a Programmed Death-1 (PD-1) mAb, to Characterize Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid Tumours

NCT03990233 is registered in ClinicalTrials.gov with OSE Immunotherapeutics as lead sponsor.

NCT NCT03990233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03990233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I Dose Finding Study of BI 765063, a Monoclonal Antibody (mAb) Antagonist of SIRPα, as Single Agent and in Combination With BI 754091, a Programmed Death-1 (PD-1) mAb, to Characterize Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid Tumours
Lead sponsor
OSE Immunotherapeutics
Phase
Phase 1
Overall status
Completed
Start date
April 16, 2019
Completion date
April 30, 2025
Enrollment
100 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult